In a murine intrahepatic tumor model, KCTD1 knockdown synergizes with anti-PD-1 therapy, resulting in enhanced tumor infiltration by CD4+ and CD8+ T lymphocytes and improved anti-tumor efficacy. Here, KCTD1 is linked to neoplasm.